Search

Displaying results 5591 - 5600 of 8697 in total
  1. Drug

    Arzoxifene

    go.drugbank.com/drugs/DB06249
    ApprovedWithdrawn

  2. Drug

    Oral Polio Vaccine

    go.drugbank.com/drugs/DB15864
    Investigational

    The polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are

  3. Drug

    RGX-181

    go.drugbank.com/drugs/DB17942
    Experimental

    Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.[L47072] … RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene.

  4. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    SAR445136 is an investigational zinc finger nuclease gene-edited cell therapy. … [A259063] It was formerly investigated for the treatment of beta-thalassemia, and it is currently being investigated for the treatment of sickle cell disease.[L46148]

  5. Drug

    Bradanicline

    go.drugbank.com/drugs/DB06090
    Investigational

    Bradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders. … Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7).

  6. Drug

    Medrysone

    go.drugbank.com/drugs/DB00253
    Approved

    Medrysone is a corticosteroid used in ophthalmology.

    Categories: Corticosteroid Hormone Receptor Agonists, P-glycoprotein substrates
  7. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematologica...

  8. Drug

    Peginesatide

    go.drugbank.com/drugs/DB08894
    ApprovedWithdrawn

    Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life.

  9. Drug

    EGT-301

    go.drugbank.com/drugs/DB17649
    Experimental

    EGT-301 is a gene therapy being investigated for Hunter Syndrome. … It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome

  10. Drug

    Coagulin-B

    go.drugbank.com/drugs/DB17703
    Experimental

    Coagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX. … [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation